Botox in 2026: Market Demand, Treatment Trends, Safety & Future Outlook

The original version of this article mixed Botox brand data, all-brand botulinum toxin procedure counts, therapeutic indications and third-party market forecasts. The 2026 picture is clearer when those categories are separated.

How Large Is the Botox Market in 2026?

The answer depends on what is being measured.

Procedure demand

The American Society of Plastic Surgeons ranked neuromodulator injections as the leading minimally invasive treatment category in 2025, accounting for 50% of all minimally invasive treatments.

ASPS did not publish an exact 2025 neuromodulator procedure count. The organization stated that because of the rapidly changing minimally invasive market, it is seeking a data source that better aligns with its cosmetic and reconstructive datasets before estimating treatment counts.

The latest directly comparable ASPS count is therefore the 2024 figure: 9,883,711 neuromodulator injections, up 4% from 2023. That category included Botox, Dysport, Xeomin, Jeuveau and Daxxify rather than Botox alone.

Global procedure volume

The latest detailed ISAPS Global Survey estimated 7,887,955 botulinum toxin procedures worldwide in 2024 among plastic surgeons. Botulinum toxin remained the most commonly performed nonsurgical procedure even though the estimate was 17.4% lower than in 2023.

What Does Botox Cosmetic Revenue Show?

For Botox specifically, AbbVie’s financial reports are more useful than a third-party estimate because they report actual brand revenue.

These figures measure Botox Cosmetic sales, not the total U.S. neuromodulator market. They also show why a single market-growth percentage can be misleading. A treatment category can remain extremely popular while one brand loses share, changes pricing or faces stronger competition.

Botox Is No Longer the Whole Neuromodulator Category

The U.S. aesthetic neuromodulator market now includes several FDA-approved products. ASPS lists Botox, Dysport, Letybo, Xeomin, Jeuveau and Daxxify among the products represented in its 2025 neuromodulator category.

Letybo became the newest U.S. entrant when the FDA approved letibotulinumtoxinA-wlbg in February 2024 for temporary improvement of moderate to severe glabellar lines in adults.

Competition matters because patients now encounter differences in brand familiarity, approved indications, dosing systems, formulation, onset claims, duration claims, loyalty programs and pricing.

Botulinum toxin units are not interchangeable between products. The Botox Cosmetic prescribing information specifically states that its potency units cannot be compared with or converted into units of another botulinum toxin product. Comparing prices purely on a per-unit basis across brands is therefore misleading.

Skin Works currently offers Botox, Dysport, Xeomin and Jeuveau.

What Is Botox Cosmetic Actually FDA-Approved to Treat?

Botox Cosmetic contains onabotulinumtoxinA and is FDA-approved in adults for temporary improvement of four aesthetic indications:

• moderate to severe glabellar lines, commonly called frown lines or the “11s”
• moderate to severe lateral canthal lines, commonly called crow’s feet
• moderate to severe forehead lines associated with frontalis muscle activity
• moderate to severe platysma bands in the neck

The platysma-band indication was approved in October 2024 and is the newest U.S. cosmetic indication for Botox Cosmetic. It expanded the labeled aesthetic use beyond the upper face into the neck.

Other cosmetic uses discussed online, including lip flips, masseter slimming, bunny lines, gummy-smile treatment and some brow-lift techniques, may be off-label. Off-label use can be medically appropriate, but it should not be described as though it carries the same FDA indication as the four approved treatment areas.

Botox Cosmetic and Therapeutic Botox Are Different Market Stories

The same active molecule, onabotulinumtoxinA, is also used medically under the Botox name for therapeutic indications. These include conditions in neurology, urology and other specialties.

That does not mean chronic migraine, overactive bladder or cervical dystonia are “Botox Cosmetic indications.” AbbVie reports Botox Cosmetic within its aesthetics portfolio and Botox Therapeutic within neuroscience.

In the second quarter of 2026, AbbVie reported $728 million in global Botox Cosmetic revenue and $1.042 billion in global Botox Therapeutic revenue. Combining those businesses into one aesthetic “Botox market size” would obscure what is actually happening.

Who Is Getting Botulinum Toxin?

Global data do not support the idea that botulinum toxin is mainly a treatment for one narrow age group.

In the ISAPS 2024 survey, adults ages 35 to 50 represented the largest share of botulinum toxin procedures at 47.0%. Adults ages 18 to 34 accounted for about 1.8 million procedures, while adults ages 51 to 64 accounted for about 1.86 million.

That broad distribution helps explain why terms such as “preventative Botox” have become common in consumer marketing. However, preventative Botox is not a separate FDA-approved indication or standardized treatment protocol. Age alone is not a reason to inject. The clinical question is whether dynamic muscle activity is creating a concern that the patient wants treated.

What About “Baby Botox” and Microdosing?

“Baby Botox” is a marketing term rather than a distinct medication or FDA-defined dosing regimen. It generally refers to using a more conservative dose or treating fewer injection points to preserve more movement.

Lower dosing can be appropriate for selected patients, but less product is not automatically better. Too little toxin may provide inadequate correction or shorter duration. The treatment plan should follow muscle strength, anatomy, treatment area and the patient’s desired degree of movement.

Intradermal “microbotox” techniques used for pores, oiliness, redness or skin texture are different from standard intramuscular wrinkle treatment and are generally off-label. Evidence for these uses is still more limited than evidence for established dynamic-line indications.

Safety Is Becoming More Important as the Market Expands

All botulinum toxin products carry important safety warnings. Botox Cosmetic has a boxed warning for potential distant spread of toxin effect. Symptoms can include generalized muscle weakness, double vision, drooping eyelids, swallowing difficulty, speech problems and breathing difficulty.

The labeled cosmetic doses have an established safety record, but appropriate patient selection, anatomy knowledge and dosing remain essential.

Product authenticity has also become a market-level safety issue. A 2024 CDC investigation identified 17 people in nine states with harmful reactions associated with counterfeit, unverified or mishandled botulinum toxin products; 13 were hospitalized. The CDC advises patients to receive injections only from licensed, trained providers using product obtained from authorized suppliers.

The FDA separately published images and identifying information for counterfeit Botox after unsafe products were found in multiple states.

That makes the supply chain part of the treatment decision. Price alone should never be the only criterion for choosing an injector or clinic.

Where Is the Research Going?

The current research pipeline extends beyond wrinkle reduction, but early findings should not be confused with approved indications.

Scar modulation

A 2026 systematic review discussed by ASPS evaluated 19 studies involving 686 patients and found that botulinum toxin type A was associated with improvements in several scar measures. The authors described the approach as promising but also called for additional research.

Using botulinum toxin to influence scar healing is not an FDA-approved cosmetic Botox indication and should still be considered investigational or off-label depending on the clinical context.

Lower-face and neck treatment

The 2024 platysma-band approval is a more concrete market development. Rather than representing speculative research, it created a new labeled aesthetic treatment area and provides formal dosing and clinical-trial data for a part of the face and neck that had long been treated off-label.

Competition and product differentiation

The future of the market is likely to involve more competition around onset, duration, formulation and patient experience. New products may gain share without reducing overall neuromodulator demand, while established brands may expand through new indications.

Current Botox Pricing at Skin Works

Current Skin Works Torrance pricing lists Botox at $12.50 per unit. The current new-patient offer is a 20-unit Botox bundle for $199.

Unit requirements vary significantly by anatomy, muscle strength and treatment area. The FDA-approved Botox Cosmetic dose for one indication should not be copied blindly to another area, and Botox units should not be converted directly into Dysport, Xeomin, Jeuveau or another toxin’s units.

For treatment areas, current offers and candidacy information, see Botox in Torrance at Skin Works.

What Is the Botox Market Outlook for 2026 and Beyond?

The most defensible outlook is not that Botox will simply grow at one fixed annual percentage.

Neuromodulator demand remains structurally strong. ASPS still ranks the category first among minimally invasive treatments, and botulinum toxin remains the leading nonsurgical procedure in the latest ISAPS global data.

Brand competition is increasing. Botox now competes in a U.S. market with multiple approved type A toxins, and AbbVie’s 2025 results showed that category popularity does not guarantee uninterrupted Botox brand growth.

Indications can expand the addressable market. The platysma-band approval added a new labeled aesthetic region for Botox Cosmetic.

Consumers are likely to become more product-aware. As more brands enter the market, authenticity, approved indications, provider licensing and transparent dosing become more important, not less.

Research will continue beyond wrinkles. Scar modulation and other dermatologic applications remain areas of study, but the quality of evidence and regulatory status should determine how aggressively those applications are marketed.

Frequently Asked Questions